December 1, 2015
Velneva’s Clostridium difficile vaccine Candidate meets Phase II trial target
Velneva’s Clostridium difficile vaccine Candidate meets Phase II trial target
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
November 30, 2015
DNA repair factor linked to breast cancer may also play a role in Alzheimer’s disease
Low levels of breast cancer factor 1 (BRCA1) protein in the brain may contribute to dementia, according to results of a National Institutes of Health (NIH)-funded study, published in Nature Communications.
November 30, 2015
Janssen asks for its Chron’s disease drug Stelara U.S. and EU approval
Janssen Biotech, Inc. and Janssen-Cilag International NV (Janssen) are seeking approval from the U.S. and European authorities for Chron’s disease drug Stelara.
November 30, 2015
European Commission approves Horizon’s Ravicti for treating Urea Cycle Disorders
Horizon Pharma and its affiliate, Horizon Therapeutics, has gotten the European Commission’s (EC’s) approval for Ravicti – glycerol phenylbutyrate – Oral Liquid for use as an adjunctive therapy for chronic management patients with six subtypes of Urea Cycle Disorders (UCDs).
November 30, 2015
In rural South Africa, AIDS treatment gains ground – but so do infections
When HIV-positive patients first came to seek treatment at the rural Uthungulu district health clinic in South Africa’s eastern KwaZulu-Natal province in 1998, their records were kept in brown folders, the colour designated for the disease.
November 30, 2015
PureTech Health launches Scientific Advisory Board
Boston-based PureTech Health plc has launched a Scientific Advisory Board (SAB) of distinguished scientists and physicians, and the expansion of PureTech’s senior team.
November 30, 2015
Allergy Therapeutics completes patient enrolment in PQBirch204 Phase II study (Allergic rhinitis)
Allergy Therapeutics, a UK-based specialist in allergy vaccines, has completed randomization with 364 patients entered into the PQBirch204 double-blind, placebo-controlled dose selection study for the specific subcutaneous immunotherapy (SCIT), Pollinex Quattro Birch.
November 30, 2015
Cipla launching low-dose Efavirenz 400 mg HIV infection therapy
Cipla launching low-dose Efavirenz 400 mg HIV infection therapy
November 30, 2015
Teva and Takeda are forming a new joint venture to operate generics in Japan
Teva and Takeda are forming a new joint venture to operate in Japan
November 30, 2015
Faron: Clevegen can be used as immunotherapy product
A publication on Clever-1 function related to Faron Pharmaceuticals’ novel cancer immunotherapy antibody Clevegen, was published in journal of the American Association of Immunology.